More recently, the FDA approved ipilimumab,11 nivolumab,12 pembrolizumab,13 and the dabrafenib plus trametinib combination (BRAF‐mutated patients only) for adjuvant therapy of high‐risk melanoma, based on significantly longer recurrence‐free survival associated with these therapeutic interventions.14 The gene discussed is BRAF; the disease is melanoma.